Balassagyarmati Dr. Kenessey Albert Korhaz Rendelointezet
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
At Balassagyarmati Dr. Kenessey Albert Korhaz Rendelointezet, most studies focus on respiratory medicine, especially chronic obstructive pulmonary disease, asthma, bronchiectasis, and other lower respiratory tract conditions. The research is aimed at testing new treatment options, easing symptoms, and reducing flare-ups and hospital-related complications.
- Chronic obstructive pulmonary disease and chronic bronchitis
- Severe and inadequately controlled asthma
- Non-cystic fibrosis bronchiectasis
- Severe viral lung infections and wheezing respiratory illness
These trials explore whether emerging inhaled, biologic, and supportive therapies can improve lung function, lower exacerbation rates, and better protect patients with long-term breathing disorders.
Nervous System Diseases
The site also contributes to neurology research, with studies centered on chronic migraine and prolonged seizure episodes. This work is designed to evaluate preventive approaches for migraine and to assess treatments that may stop seizures more quickly and safely.
- Chronic migraine in adolescents
- Stereotypical prolonged seizure
- Treatment of long seizure episodes
Overall, the neurological trials at this hospital in Hungary are focused on improving symptom control, safety, and day-to-day quality of life for patients with recurring or urgent neurological conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB3active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB6trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Balassagyarmati Dr. Kenessey Albert Korhaz Rendelointezet
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO). | AstraZeneca AB | Phase II | Recruiting | Sep 2025 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Formoterol Fumarate Dihydrate | 4 | Unknown | 2021-04-29 | 2024-06-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.